Gretel, Illumina partner to develop synthetic data for genomic research

By The Science Advisory Board staff writers

December 16, 2021 -- Gretel announced a collaboration with Illumina to create synthetic genomic data that can be accessed by medical researchers globally. The companies also announced the release of a case study the partnership conducted that explores significant new use cases for synthetic data in genomics and related fields, including medical diagnosis, biotechnology, forensic biology, virology, and biological systematics.

The partnership will provide healthcare and life science practitioners access to highly statistically accurate, artificial versions of complex genomic datasets that align with the General Data Protection Regulation, the California Consumer Protection Act, and other major privacy laws. By using synthetic data, researchers can gain access to datasets immediately and avoid lengthy approval processes by institutional review boards, the firms said.

Additionally, this privacy-preserving method of sharing sensitive data allows for an accelerated and collaborative approach to next-generation DNA sequencing analysis, leading to the discovery of new drugs, insights into genetic disorders, and disease detection and treatments, the companies noted.

Illumina supports Norway's pioneering precision medicine study
Illumina announced that it is supporting a precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling in...
Startups selected for Illumina's genomics incubator in China
Illumina and investment firm Sequoia Capital China have selected the first two startups to join the Sequoia Capital China Intelligent Healthcare Genomics...
Illumina for Startups pushes boundaries of genomics by supporting early-stage companies
Most scientists are familiar with the genomics giant Illumina, which is known for its DNA sequencing technologies. However, Illumina has an accelerator...
Illumina Accelerator invests in 9 genomics startups
Illumina picked nine genomics companies to join the second global funding cycle of the Illumina Accelerator in the U.S. and U.K.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter